Merck Group

Laboratory Proficiency Testing Market worth $1.6 billion | MarketsandMarkets

Retrieved on: 
Wednesday, October 4, 2023

In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.

Key Points: 
  • In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.
  • In 2022, the cell culture segment held the largest market share in the Laboratory Proficiency Testing market.
  • The APAC Laboratory Proficiency Testing market is projected to grow at the highest rate during the forecast period.
  • The laboratory proficiency testing market is segmented into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Laboratory Proficiency Testing Market worth $1.6 billion | MarketsandMarkets

Retrieved on: 
Wednesday, October 4, 2023

In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.

Key Points: 
  • In 2022, the clinical diagnostics segment accounted for the largest share of the laboratory proficiency testing market.
  • In 2022, the cell culture segment held the largest market share in the Laboratory Proficiency Testing market.
  • The APAC Laboratory Proficiency Testing market is projected to grow at the highest rate during the forecast period.
  • The laboratory proficiency testing market is segmented into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Exscientia Details Pipeline Prioritisation Strategy

Retrieved on: 
Tuesday, October 3, 2023

Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today provided an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation.
  • Exscientia has built a highly efficient and versatile AI-led drug discovery platform.
  • This strategic focus is designed to allow Exscientia to maximise its pipeline value and output while continuing to develop novel technologies to transform drug discovery and development.
  • “Exscientia creates value by using technology to solve previously unsolved discovery challenges and achieving great data-driven operating efficiency,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, October 2, 2023

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

Key Points: 
  • Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.
  • The PARPA Phase 1 studies, PARPA-293-001 and PARPA-293-002 are evaluating NMS-03305293 (NMS-293), an oral, brain-penetrant PARP-1 selective inhibitor as single agent or in combination with temozolomide, in relapsed/refractory selected solid tumor types (PARPA-293-001) or patients with High-grade gliomas (PARPA-293-002, including glioblastoma).
  • On September 14, 2022, NMS Group entered into a worldwide option agreement with Merck KGaA, Darmstadt, Germany for the development and commercialization of NMS-293.
  • Details for the plenary and poster presentations are as follows:
    Title: Initial Results from 2 Phase I Studies of NMS-03305293, a Selective PARP1 Inhibitor

Real-World Evidence and Data Analytics Conference (Frankfurt, Germany - October 5-6, 2023): Paving the Path for Next-Gen Medicinal Research

Retrieved on: 
Friday, September 29, 2023

DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.
  • Building on five triumphant installments held in Boston, USA, this year's European chapter promises an invigorating assembly of experts, leaders, and stakeholders.
  • The confluence aims to shed light on the accelerating evolution of real-world evidence (RWE) and its vital impact on drug benefit elucidation.
  • Its pivotal role in patient monitoring through digital platforms, coupled with aiding clinical data organization for regulatory inclusions, is noteworthy.

Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration

Retrieved on: 
Thursday, September 28, 2023

This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches.

Key Points: 
  • This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches.
  • Merck KGaA, Darmstadt, Germany will now further leverage Quris-AI platform’s ability to effectively identify liver toxicity risks in a selection of drug candidates.
  • Subsequently, Merck KGaA, Darmstadt, Germany has the option to obtain up to a five-year exclusive license to a specific disease domain.
  • Upon Merck KGaA, Darmstadt, Germany exercising the option, Quris-AI may receive an undisclosed amount.

Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products

Retrieved on: 
Thursday, September 28, 2023

Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.

Key Points: 
  • Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.
  • Triastek’s proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development methods, enables complex drug delivery and programmed release.
  • Triastek, as a leading provider of digital pharmaceutical process technology, is continuously advancing applications of 3D printing technology to produce novel pharmaceutical products that improve patient outcomes.
  • The company has engaged in extensive business collaborations with global pharmaceutical companies, focusing on novel products and advanced technical solutions.

Syntropy Announces Collaboration with Evidium to Advance Data-Centric Healthcare

Retrieved on: 
Wednesday, September 27, 2023

The healthcare industry will also benefit from Evidium’s methods that responsibly use AI and Syntropy’s ethical data practices.

Key Points: 
  • The healthcare industry will also benefit from Evidium’s methods that responsibly use AI and Syntropy’s ethical data practices.
  • "Together, Syntropy and Evidium will work to make clinical research computable and scalable by simplifying the process of entering quality medical data onto a secure, trustworthy platform.
  • Syntropy enables researchers, healthcare institutions, and other healthcare stakeholders to contribute, share, view, and collaborate on data in a secure, unified platform.
  • Syntropy plus Evidium enables this vision for our customers.”
    Eventually, the offering will be expanded to more healthcare and biopharmaceutical organizations, with the goal of positively impacting patient quality and experience.

CellFE secures $22 million in Series A financing to advance microfluidics-based cellular engineering platform

Retrieved on: 
Wednesday, September 27, 2023

Therapy developers are forging partnerships with technology providers, such as CellFE, to advance innovative solutions, with the aim to benefit patients seeking better therapeutic options.

Key Points: 
  • Therapy developers are forging partnerships with technology providers, such as CellFE, to advance innovative solutions, with the aim to benefit patients seeking better therapeutic options.
  • CellFE's innovative, non-viral, microfluidic cell engineering platform, Infinity MTx™ system, performs complex genetic cell editing through streamlined, advanced workflows.
  • "Our vision of advancing the platform to a decentralized and point of care application will expand access to cell therapies for millions of patients."
  • CellFE presents a unique technology platform addressing key industry pain points across viral, but also other non-viral methods," said Christian Uhrich, Principal at M Ventures.

Indium Tin Oxide Market size to increase by USD 213.87 million between 2022 to 2027| Amalgamated Metal Corp. PLC, American Elements, Diamond Coatings Inc. and more among key companies- Technavio

Retrieved on: 
Wednesday, September 27, 2023

Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.

Key Points: 
  • Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.
  • Buy the report now for detailed company information
    Indium Tin Oxide Market 2023-2027: Company Analysis:
    Ulvac Inc.: The company offers indium tin oxide products such as NE 5700 and SIV series systems.
  • View Free PDF Sample Report
    Indium Tin Oxide Market 2023-2027: Market Dynamics:
    Driver - The increasing usage of touchscreen devices is a key factor driving market growth.
  • For more information on drivers, trends and challenges, download the free sample report here
    Indium Tin Oxide Market 2023-2027: Key Highlights
    How do the major trends impact the market?